In accordance with feedback from the Danish Medicines Agency we have performed additional safety studies for SIS in a minipig inhalation model, resembling the human respiratory tract. This study confirmed that mild changes to the respiratory epithelium when exposed with higher concentrations of SIS have been documented to be transient and fully reversible,” says DVM Elin Jørgensen from University of Copenhagen (in charge of animal studies).
SoftOx Inhalation Solution (SIS) is an inhalation solution where the hypothesis is that it should be able to treat all types of respiratory tract infections. This could potentially be a paradigm shift in the treatment of all types of respiratory infections.
“Safety-wise, these results are of outmost importance to SoftOx, as it provides excellent grounds for pursuing safety testing in humans as planned in Q2 2021,” says Medical Director at SoftOx, Glenn Gundersen.
“This is excellent news and support our aim for SIS to become a well-tolerated and effective treatment for COVID-19 patients and potentially other respiratory infections,” says Professor in Microbiology and Primary Investigator Thomas Bjarnsholt*, University of Copenhagen and Rigshospitalet, Denmark.
*Professor Bjarnsholt is one of the inventors of the SoftOx technology, and he is a member of the SoftOx Solutions AS advisory board. He owns options (20 000) to acquire shares in the company, and he is being paid for his work for SoftOx Solutions AS.
Oslo, 16 December 2020
Contact:
Geir Almås, CEO of SoftOx Solutions AS
Email: geir.almaas@soft-ox.com
Mobile: +47 977 59 071
About SoftOx Solutions AS SoftOx Solutions AS (SoftOx, listed on the Oslo Stock Exchange Euronext Growth) is a Norwegian MedTech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com